-
Mutant KRAS Vaccine Boosts Pancreatic Cancer Therapy
11 Feb 2026 03:25 GMT
… targeting of mutant KRAS epitopes harnesses tumor … KRAS mutations are prevalent in several other malignancies, including colorectal and lung cancers … Title: Mutant KRAS vaccine with dual … pancreatic cancer patientsmutant KRAS vaccinenovel therapeutic strategies …
-
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
11 Feb 2026 13:45 GMT
… key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and … highly relevant in GI and lung cancers. For more information about the …
-
Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer
02 Feb 2026 13:58 GMT
… KRAS mutation. Tumors harboring KRAS/STK11 or KRAS… PD-L1 immunohistochemistry in lung cancer. Lung Cancer. 2022;166:143– … DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl … PD-L1 positive lung cancer patients. Lung Cancer. 2020;150: …
-
Lung Cancer Molecular Biomarker Industry Outlook to 2036: Strategic Insights for R&D, Expansion, and Market Development
23 Jan 2026 13:18 GMT
… the Lung Cancer Molecular Biomarker Market?
The Lung Cancer Molecular … EGFR, ALK, ROS1, KRAS, PD-L1 expression, … oncology adoption, increasing lung cancer incidence, and growing … Industry Stakeholders
The Lung Cancer Molecular Biomarker Market …
-
Lung Cancer Molecular Biomarker Industry Outlook to 2036: Strategic Insights for R&D, Expansion, and Market Development
22 Jan 2026 21:07 GMT
… the Lung Cancer Molecular Biomarker Market?
The Lung Cancer Molecular … EGFR, ALK, ROS1, KRAS, PD-L1 expression, … oncology adoption, increasing lung cancer incidence, and growing … Industry Stakeholders
The Lung Cancer Molecular Biomarker Market …
-
STCube begins dosing in P2 trial of nelmastobart for lung cancer
22 Jan 2026 07:03 GMT
… or metastatic non-small cell lung cancer (NSCLC).
The phase 2 study … mutations in genes like EGFR, KRAS, or BRAF. For cases without …
-
Lung Cancer Therapeutics Market Valuation, ROI Potential & Long-Term Growth Prospects 2026–2036
20 Jan 2026 17:15 GMT
… rearrangements in non-small cell lung cancer (NSCLC). Immunotherapies, including checkpoint … tyrosine kinase inhibitors, and KRAS inhibitors. Immunotherapies and angiogenesis … , North America leads the lung cancer therapeutics market, benefiting from …
-
Filamentous Phage for Therapeutic Applications in Non-Small Cell Lung Cancer and Brain Metastases: Recent Prospect
19 Jan 2026 18:47 GMT
… , ALK fusions, and KRAS mutations. For instance, … phages specifically binding to lung cancer tumors.
Principles of … successfully applied to target lung cancer cells, especially brain … ligands in lung cancer patients or using transplanted lung cancer animal …
-
PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
11 Feb 2026 01:51 GMT
… Cancer, Non-small Cell Lung Cancer (NSCLC), and others.
… that selectively degrades the KRAS G12D protein and represents … Cancer, Non-small Cell Lung Cancer (NSCLC), and others
… small Cell Lung Cancer Market
Non-small Cell Lung Cancer Market Insights, …
-
Air Force veteran left in constant pain after lung cancer diagnosis gets life back through trial at Moffitt
15 Jan 2026 04:09 GMT
… ;KRAS G12D," which affects about 2% of lung cancer patients … Barry Manilow reveals early lung cancer diagnosis, says no chemo … you should care: Lung cancer remains the leading cause … treatment options for lung cancer patients with the KRAS G12D mutation. …
About
© 1995-2026